These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18518978)

  • 1. Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses.
    Ainsworth J; Thomas M; Banks L; Coutlee F; Matlashewski G
    Virol J; 2008 Jun; 5():67. PubMed ID: 18518978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
    Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
    Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of MAGI-1 expression in human papillomavirus-positive tumor cells induces cell growth arrest and apoptosis.
    Kranjec C; Massimi P; Banks L
    J Virol; 2014 Jul; 88(13):7155-69. PubMed ID: 24696483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation.
    Thomas M; Laura R; Hepner K; Guccione E; Sawyers C; Lasky L; Banks L
    Oncogene; 2002 Aug; 21(33):5088-96. PubMed ID: 12140759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
    Massimi P; Shai A; Lambert P; Banks L
    Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein.
    Pim D; Tomaic V; Banks L
    J Virol; 2009 Oct; 83(19):9863-74. PubMed ID: 19640984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation.
    Thomas M; Glaunsinger B; Pim D; Javier R; Banks L
    Oncogene; 2001 Sep; 20(39):5431-9. PubMed ID: 11571640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor.
    Padash Barmchi M; Gilbert M; Thomas M; Banks L; Zhang B; Auld VJ
    PLoS Pathog; 2016 Aug; 12(8):e1005789. PubMed ID: 27537218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.
    Bernard X; Robinson P; Nominé Y; Masson M; Charbonnier S; Ramirez-Ramos JR; Deryckere F; Travé G; Orfanoudakis G
    PLoS One; 2011; 6(10):e25981. PubMed ID: 22046250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions.
    Kranjec C; Banks L
    J Virol; 2011 Feb; 85(4):1757-64. PubMed ID: 21123374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
    Drews CM; Case S; Vande Pol SB
    PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
    Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
    J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
    Camus S; Higgins M; Lane DP; Lain S
    FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.
    Thatte J; Massimi P; Thomas M; Boon SS; Banks L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29848585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
    Stewart D; Kazemi S; Li S; Massimi P; Banks L; Koromilas AE; Matlashewski G
    J Gen Virol; 2004 Jun; 85(Pt 6):1419-1426. PubMed ID: 15166424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo.
    Nguyen ML; Nguyen MM; Lee D; Griep AE; Lambert PF
    J Virol; 2003 Jun; 77(12):6957-64. PubMed ID: 12768014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1.
    Fournane S; Charbonnier S; Chapelle A; Kieffer B; Orfanoudakis G; Travé G; Masson M; Nominé Y
    J Mol Recognit; 2011; 24(4):511-23. PubMed ID: 20842623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into the interaction of HPV-16 E6 variants against MAGI-1 PDZ1 domain.
    Araujo-Arcos LE; Montaño S; Bello-Rios C; Garibay-Cerdenares OL; Leyva-Vázquez MA; Illades-Aguiar B
    Sci Rep; 2022 Feb; 12(1):1898. PubMed ID: 35115618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of E6AP-independent degradation targets of HPV E6.
    Vats A; Thatte J; Banks L
    J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.